BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-1681 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-1681\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06737731-11119@assetmemo.bio
DTSTAMP:20261121T005609Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:SHR-1681: Phase 1/2 readout est. (NCT06737731)
DESCRIPTION:SHR-1681\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Phase I
 /II Clinical Study of SHR-1681 for Injection in Patients With Advanced Sol
 id Tumors\nEstimated primary completion: November 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/shr-1681#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06737731
URL:https://assetmemo.bio/drug/shr-1681#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
